NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.

NCT04633967

CompletedN/A

Sponsor: Maritime Neurology

Conditions: Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis

Interventions: Alemtuzumab Injection

Countries: Canada

To evaluate a Novel infusion protocol in MS patients treated with Alemtuzumab

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria: Patient s treated with Alemtuzumab as per canadian label -

Exclusion Criteria: Contraindication to Alemtuzumab

\-

Locations (1)

Halifax, Nova Scotia, Canada